.jpg?format=webp&width=780)
To assess the effect of SGLT2 inhibitor dapagliflozin on natriuresis, blood pressure (BP) and volume status in patients with CKD without diabetes. In DAPASALT (mean age 65 years, mean eGFR 39.4 ml/min/1.73m2, median UACR 111 mg/g), dapagliflozin did not change 24‐hr sodium and volume excretion during 2 weeks of treatment. During a standardized sodium diet, dapagliflozin decreased BP but did not increase 24‐hr sodium and volume excretion. The lack of increased natriuresis and diuresis may be attributed to the activation of intra‐renal compensatory mechanisms to prevent excessive water loss.
Like
Save
Share